Frontlight ResearchEarly access
Taking people in United StatesPhase 1
A Phase 1, Dose Escalation Trial of RP-A601 in Subjects With PKP2 Variant-Mediated Arrhythmogenic Cardiomyopathy (PKP2-ACM)
Key facts
- Who runs it
- Rocket Pharmaceuticals Inc.
- Where
- Durham, La Jolla, and Philadelphia, United StatesSee the 3 sites
- Trial code
- Status
- Recruiting
- Phase
- Phase 1
- People taking part
- 9 people, planned
- Started
- 29 Aug 2023
- Expected to end
- Sept 2029
- Type of study
- Interventional
- Treatments tested
- RP-A601
- Record updated
- 16 April 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 12 criteriaShow less
Who can take part
- Male or female ≥18 years at the time of signing the informed consent
- Capable and willing to provide signed informed consent
- Clinical diagnosis of ACM as defined by the 2010 revised Task Force Criteria (TFC)
- Documentation of a pathogenic or likely pathogenic truncating variant in PKP2
- History of Implantable Cardioverter-Defibrillator (ICD) implantation ≥6 months prior to enrollment
- PVC frequency ≥500 per 24 hours by ambulatory rhythm monitoring
- Left ventricular ejection fraction by echocardiogram or CMR ≥50%
Who cannot take part
- Anti-AAVrh.74 capsid neutralizing antibody titer of >1:40
- Previous participation in a study of gene transfer or gene editing
- New York Heart Association (NYHA) Class IV heart failure
- Cardiomyopathy related to a genetic etiology other than PKP2 truncating variant
- Severe Right Ventricular (RV) dysfunction
This trial is currently available in United States.
- Duke UniversityDurham, United StatesContact: Meghan Pergola, MPHTaking people
- University of California San DiegoLa Jolla, United StatesContact: Barry Greenberg, MDTaking people
- Children's Hospital of PhiladelphiaPhiladelphia, United StatesNo longer taking part
About the trial
What the trial wants to find out
This Phase 1 dose escalation trial will assess the safety and preliminary efficacy of a single dose intravenous infusion of RP-A601 in high-risk adult patients with PKP2-ACM.
The group in the trial
- RP-A601Treatment being tested
Single ascending dose of RP-A601 in 2 consecutive cohorts
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Phase 1 Dose Escalation Trial Evaluating an Intravenously Administered Recombinant Adeno-Associated Virus Serotype rh.74 (AAVrh.74) Vector Containing the Human Plakophilin-2a (PKP2a) Coding Sequence (RP-A601; AAVrh.74-PKP2a) in Subjects With Arrhythmogenic Cardiomyopathy Arising From Pathogenic PKP2 Variants (PKP2-ACM)
- Publications
- Anticoagulation in patients with atrial fibrillation and heart failure: More than meets the eye?International journal of cardiology, 2024
- Record updated
- 16 April 2026